DNAJA1 and chronic myelogenous leukemia, BCR-ABL1 positive: By screening the NCI-approved oncology drugs collection in human chronic myelogenous leukemia HAP1 cell line with or without DNAJA1/HDJ2 knockout, 41 compounds, including cabozantinib, clofarabine, and vinblastine, are identified as drugs that show synergy with DNAJA1/HDJ2 loss [79].